Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

PloS one

Volumn 9, Issue 9, 2014, Pages e110069-

  Sha, Sue ^a   Devineni, Damayanthi ^a   Ghosh, Atalanta ^a   Polidori, David ^a   Hompesch, Marcus ^a   Arnolds, Sabine ^a   Morrow, Linda ^a   Spitzer, Heike ^a   Demarest, Keith ^a   Rothenberg, Paul ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; GLUCOSE BLOOD LEVEL; INSULIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ANTAGONISTS AND INHIBITORS; BLOOD; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOSURIA; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; URINALYSIS;

EID: 84953342451     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110069     Document Type: Article

References (0)